Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II/III Study of Individualized Neoadjuvant Chemotherapy in ' Triple Negative' Breast Tumors

NCT01057069 is registered in ClinicalTrials.gov with The Netherlands Cancer Institute as lead sponsor.

NCT NCT01057069
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01057069 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II/III Study of Individualized Neoadjuvant Chemotherapy in ' Triple Negative' Breast Tumors
Lead sponsor
The Netherlands Cancer Institute
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
January 31, 2010
Completion date
December 31, 2029
Enrollment
310 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer